Market Overview:
The global depression drugs market reached a value of US$ 12.7 Billion in 2020. Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.
According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Apart from this, with the surge in the cases of the coronavirus disease (COVID-19), there is a considerable degree of fear, worry and concern in the population. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years. Looking forward, the global depression drugs market is expected to grow at a CAGR of around 3% during the forecast period (2021-2026).
IMARC Group’s latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global depression drugs market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug class, disorder type, drug type, and distribution channel.
Report Coverage:
- Historical, Current and Future Market Trends
- Market Breakup by Drug Class:
- Atypical Antipsychotics
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Central Nervous System (CNS) Stimulants
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
- Others
- Market Breakup by Disorder Type:
- Major Depressive Disorder
- Obsessive-Compulsive Disorder
- Generalized Anxiety Disorder
- Panic Disorder
- Others
- Market Breakup by Drug Type:
- Generic Drugs
- Branded Drugs
- Market Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Market Breakup by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Competitive Landscape:
The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.
Key Questions Answered in This Report
The global depression drugs market size was valued at US$ 12.70 Billion in 2020.
According to the estimates by IMARC Group, the global depression drugs market is expected to witness a CAGR of 3% from 2021 to 2026.
The increasing prevalence of social anxiety and depression due to increasing work pressure and busy schedules, represents one of the key drivers for the global depression drugs market.
The emergence of novel techniques for developing antidepressants with minimal side-effects and long-term results, in confluence with the rising acceptance of new medications, represent some of the key trends in the global depression drugs market.
Sudden outbreak of the COVID-19 pandemic had negatively impacted the mental health of individuals due to the imposition of lockdown regulations, loss of employments, increased health risks, etc., which are augmenting the demand for depression drugs.
On the basis of the disorder type, the market has been bifurcated into major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, panic disorder and others. Currently, major depressive disorder holds the majority of the total market share.
On the basis of the distribution channel, the market has been segmented into retail pharmacies, hospital pharmacies, online pharmacies and other pharmacies. At present, retail pharmacies exhibit a clear dominance in the market.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global depression drugs market are Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Depression Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Drug Class
5.5 Market Breakup by Disorder Type
5.6 Market Breakup by Drug Type
5.7 Market Breakup by Distribution Channel
5.8 Market Breakup by Region
5.9 Market Forecast
6 Market Breakup by Drug Class
6.1 Atypical Antipsychotics
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Central Nervous System (CNS) Stimulants
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Tricyclic Antidepressants
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Monoamine Oxidase Inhibitors
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Disorder Type
7.1 Major Depressive Disorder
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Obsessive-Compulsive Disorder
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Generalized Anxiety Disorder
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Panic Disorder
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Drug Type
8.1 Generic Drugs
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Branded Drugs
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Europe
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Asia Pacific
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Middle East and Africa
10.4.1 Market Trends
10.4.2 Market Forecast
10.5 Latin America
10.5.1 Market Trends
10.5.2 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porter’s Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Otsuka Pharmaceutical
15.3.2 Pfizer
15.3.3 Eli Lilly and Company
15.3.4 AstraZeneca
15.3.5 Novartis
15.3.6 Bristol-Myers Squibb
15.3.7 GlaxoSmithKline
15.3.8 Takeda Pharmaceutical Company
15.3.9 Allergan
15.3.10 Johnson & Johnson
15.3.11 Zhejiang NHU Company Ltd
15.3.12 Sebela Pharmaceuticals
List of Figures
Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
Figure 2: Global: Depression Drugs Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2020
Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2020
Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2020
Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2020
Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2020
Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 9: Global: Depression Drugs Industry: SWOT Analysis
Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
Figure 11: Global: Depression Drugs Industry: Porter’s Five Forces Analysis
Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million US$), 2015 & 2020
Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulant) Market: Sales Value (in Million US$), 2015 & 2020
Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulant) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million US$), 2015 & 2020
Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2015 & 2020
Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million US$), 2015 & 2020
Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million US$), 2015 & 2020
Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million US$), 2015 & 2020
Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million US$), 2015 & 2020
Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million US$), 2015 & 2020
Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million US$), 2015 & 2020
Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million US$), 2015 & 2020
Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2015 & 2020
Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2021-2026
Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million US$), 2015 & 2020
Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2021-2026
Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million US$), 2015 & 2020
Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2021-2026
Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million US$), 2015 & 2020
Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2021-2026
Figure 48: North America: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 50: Europe: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
List of Tables
Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2021-2026
Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million US$), 2021-2026
Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 7: Global: Depression Drugs Market Structure
Table 8: Global: Depression Drugs Market: Key Players